Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Cantor Fitzgerald
Accenture
Cipla
Boehringer Ingelheim
Moodys
McKesson
Cerilliant
Covington
Fish and Richardson

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,987,103

« Back to Dashboard

Which drugs does patent 6,987,103 protect, and when does it expire?

Patent 6,987,103 protects SYNRIBO and is included in one NDA.

This patent has seventeen patent family members in twelve countries.
Summary for Patent: 6,987,103
Title:Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
Abstract: The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising: (a) selecting or identifying an animal suffering from chronic myelogenous leukemia or a related myeloproliferative disorder and showing resistance or intolerance to treatment with STI571; and (b) administering to the animal homoharringtonine. In a preferred embodiment, the animal is a human being.
Inventor(s): Robin; Jean-Pierre (Charlottesville, VA), Mahon; Francois-Xavier (Bordeaux, FR), Maisonneuve; Herve (La Roche sur Yon, FR), Maloisel; Frederick (Illkirch Graffenstaden, FR), Blanchard; Julie (Rouillon, FR)
Assignee: Stragen Pharma S.A. (Geneva, CH)
Application Number:10/397,267
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,987,103

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,987,103

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 451106 ➤ Subscribe
Austria 548041 ➤ Subscribe
Australia 2002337410 ➤ Subscribe
Canada 2459822 ➤ Subscribe
Cyprus 1109799 ➤ Subscribe
Cyprus 1112817 ➤ Subscribe
Germany 60234708 ➤ Subscribe
Denmark 1443933 ➤ Subscribe
Denmark 2177223 ➤ Subscribe
European Patent Office 1443933 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Harvard Business School
Federal Trade Commission
US Department of Justice
Argus Health
AstraZeneca
Moodys
Julphar
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot